Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

This study is currently recruiting participants.
Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Breast Cancer
			Colorectal Cancer
			Head and Neck Cancer
			Kidney Cancer
			Lung Cancer
			Ovarian Cancer
			Pancreatic Cancer
			Prostate Cancer
			Sarcoma
			Small Intestine Cancer
2		Additional conditions recognized in this trial
			Breast Neoplasms
			Carcinoma, Renal Cell
			Colorectal Neoplasms
			Duodenal Neoplasms
			Head and Neck Neoplasms
			Ileal Neoplasms
			Intestinal Neoplasms
			Jejunal Neoplasms
			Kidney Neoplasms
			Lung Neoplasms
			Ovarian Neoplasms
			Pancreatic Neoplasms
			Prostatic Neoplasms
3		More general conditions related to this trial
			Adenocarcinoma
			Adnexal Diseases
			Breast Diseases
			Carcinoma
			Colonic Diseases
			Digestive System Diseases
			Digestive System Neoplasms
			Duodenal Diseases
			Endocrine Gland Neoplasms
			Endocrine System Diseases
			Gastrointestinal Diseases
			Gastrointestinal Neoplasms
			Genital Diseases, Female
			Genital Diseases, Male
			Genital Neoplasms, Female
			Genital Neoplasms, Male
			Gonadal Disorders
			Ileal Diseases
			Intestinal Diseases
			Jejunal Diseases
			Kidney Diseases
			Lung Diseases
			Neoplasms
			Neoplasms by Histologic Type
			Neoplasms by Site
			Neoplasms, Connective and Soft Tissue
			Neoplasms, Glandular and Epithelial
			Ovarian Diseases
			Pancreatic Diseases
			Prostatic Diseases
			Rectal Diseases
			Respiratory Tract Diseases
			Respiratory Tract Neoplasms
			Skin Diseases
			Thoracic Neoplasms
			Urogenital Neoplasms
			Urologic Diseases
			Urologic Neoplasms
4		Interventions listed in this trial
			bortezomib
			gemcitabine hydrochloride
			pharmacological study
5		Additional drug interventions recognized in this trial
			Gemcitabine
6		More general drug interventions related to this trial
			Anti-Infective Agents
			Antimetabolites
			Antimetabolites, Antineoplastic
			Antineoplastic Agents
			Antiviral Agents
			Enzyme Inhibitors
			Immunologic Factors
			Immunosuppressive Agents
			Molecular Mechanisms of Pharmacological Action
			Pharmacologic Actions
			Physiological Effects of Drugs
			Protease Inhibitors
			Radiation-Sensitizing Agents
			Therapeutic Uses
7		Sponsors listed in this trial
			Masonic Cancer Center, University of Minnesota
			National Cancer Institute (NCI)